Enanta Pharmaceuticals (STU:9EP) Accounts Payable: €3.77 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
59 GF Score
Price €11.10
GF Value €7.50
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Accounts Payable?

Enanta Pharmaceuticals STU:9EP -1.77% 59 Accounts Payable is €3.77 Mil as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 59/100 and a GF Value™ of €7.50 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Enanta Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was €3.77 Mil.

Enanta Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (€1.66 Mil) to Dec. 2025 (€1.61 Mil) but then increased from Dec. 2025 (€1.61 Mil) to Mar. 2026 (€3.77 Mil).

Enanta Pharmaceuticals's annual Accounts Payable increased from Sep. 2023 (€3.84 Mil) to Sep. 2024 (€7.21 Mil) but then declined from Sep. 2024 (€7.21 Mil) to Sep. 2025 (€1.66 Mil).

Enanta Pharmaceuticals Accounts Payable Related Terms

Enanta Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Accounts Payable Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.11 6.06 3.84 7.21 1.66

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 3.08 1.66 1.61 3.77
STU:9EP
59GF Score
Enanta Pharmaceuticals Inc STU:9EP
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €3.77 Mil mean?
Enanta Pharmaceuticals (STU:9EP) has a Accounts Payable of €3.77 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Accounts Payable too high?
Enanta Pharmaceuticals' current Accounts Payable is €3.77 Mil. Overall, Enanta Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Accounts Payable compare to PBYI and IPSC?
Enanta Pharmaceuticals' Accounts Payable of €3.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Accounts Payable is €3.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.50, compared to a current price of €11.10 — trading 48% above its estimated fair value. The current Accounts Payable is €3.77 Mil. Enanta Pharmaceuticals' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current Accounts Payable is €3.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.10 is trading 48% above its estimated GF Value™ of €7.50. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • Accounts Payable: €3.77 Mil
  • GF Value™: €7.50 vs. price of €11.10 (48% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
59GF Score

Get the complete analysis for STU:9EP

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.10
Price
€7.50
GF Value